Revance Therapeutics reported $85.21M in Stock for its fiscal quarter ending in September of 2024.



Stock Change Date
AbbVie USD 4.95B 13M Dec/2025
ALKERMES USD 196.62M 5.63M Dec/2025
Bristol-Myers Squibb USD 2.76B 21M Sep/2025
Cara Therapeutics USD 900K 0 Mar/2025
Coherus Biosciences USD 3.17M 1.12M Dec/2025
Eli Lilly USD 13.74B 1.56B Dec/2025
J&J USD 14.19B 45M Dec/2025
Merck USD 6.44B 157M Sep/2025
Neurocrine Biosciences USD 69M 300K Dec/2025
P&G USD 7.82B 31M Dec/2025
Pacira USD 152.86M 4.82M Dec/2025
Supernus Pharmaceuticals USD 107.1M 63.08M Sep/2025